Abbott CEO Explains Lowered Guidance Due to China's Slower Diagnostic Recovery

Q2 Performance and Credibility

• 🎯 Abbott delivered strong Q2 results, including high single-digit sales growth and 11% EPS growth, exceeding street expectations.
• ✅ The company also achieved gross margin expansion of 100 basis points and managed tariffs effectively, demonstrating their commitment to delivering on promises.

Diagnostic Business Challenges in China

• ⚠️ The primary reason for lowering guidance was the unexpectedly slow recovery in China's diagnostic business.
• 📈 While other regions like the United States (7% growth), Europe (8% growth), and Latin America (16% growth) showed recovery, China did not meet projections.
• 🗓️ Abbott has delayed the anticipated recovery in China from Q2 to Q4.

Company Fundamentals Remain Strong

• 💰 Despite the China-specific issue, Abbott maintains its 2026 guidance for high single-digit growth and double-digit EPS.
• 📊 The company's overall revenue is $44.5 billion, with double-digit EPS growth and significant margin expansion expected.
• 🔍 Analysts have largely maintained their price targets and forecasts, suggesting the current situation is a temporary setback rather than a fundamental problem.
• 💡 The core fundamentals of the rest of Abbott's business are reported as intact.